Cyproterone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573156

CAS#: 2098-66-0

Description: Cyproterone is an anti-androgen. It is used as a palliative in prostatic carcinoma and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.


Chemical Structure

img
Cyproterone
CAS# 2098-66-0

Theoretical Analysis

MedKoo Cat#: 573156
Name: Cyproterone
CAS#: 2098-66-0
Chemical Formula: C22H27ClO3
Exact Mass: 374.16
Molecular Weight: 374.910
Elemental Analysis: C, 70.48; H, 7.26; Cl, 9.46; O, 12.80

Price and Availability

Size Price Availability Quantity
10mg USD 230
25mg USD 360
50mg USD 545
Bulk inquiry

Synonym: Androcur, BAY 94-8367, Ciproterone, Cyproterone, SH 80881

IUPAC/Chemical Name: (2aR,3aS,3bS,3cS,5aS,6R,8aS,8bR)-6-acetyl-10-chloro-6-hydroxy-3b,5a-dimethyl-3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-2(2aH)-one

InChi Key: DUSHUSLJJMDGTE-ZJPMUUANSA-N

InChi Code: 1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1

SMILES Code: C1=2[C@@]([C@@H]3[C@@H](C(=O)C2)C3)([C@@H]2[C@@H]([C@@H]3[C@@]([C@](C(C)=O)(O)CC3)(C)CC2)C=C1Cl)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 374.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Barradell LB, Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging. 1994 Jul;5(1):59-80. doi: 10.2165/00002512-199405010-00006. PMID: 7919640.


2: Mothes C. Cyproterone acetate. Lancet. 1976 Nov 6;2(7993):1020. doi: 10.1016/s0140-6736(76)90851-5. PMID: 62231.


3: Pinganaud G, Chaslerie A, Bourdel Marchasson I, Decamps A, Manciet G, Emeriau JP. Cyproterone-induced hepatotoxicity. Ann Pharmacother. 1995 Jun;29(6):634. doi: 10.1177/106002809502900619. PMID: 7663042.


4: de Voogt HJ. Cyproterone acetate as monotherapy in prospective randomized trials. Prog Clin Biol Res. 1990;359:85-91; discussion 105-7. PMID: 2149459.


5: Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am. 1991 Feb;18(1):111-22. PMID: 1825143.


6: Paulsen CA. Letter: Cyproterone acetate. Lancet. 1976 Jun 5;1(7971):1246. PMID: 58294.


7: Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol. 1991;98(2):71-80. doi: 10.1055/s-0029-1211103. PMID: 1838080.


8: Neumann F, Wiechert R. Das Antiandrogen Cyproteronacetat. Seine Geschichte von der Entdeckung bis zur Marktreife [The antiandrogen cyproterone acetate. Its history from discovery to marketing]. Pharm Unserer Zeit. 1988 Mar;17(2):33-50. German. doi: 10.1002/pauz.19880170202. PMID: 2967500.


9: Chapman MG, Jeffcoate SL, Dewhurst J. Cyproterone acetate and adrenosuppression. Lancet. 1981 Aug 22;2(8243):417. doi: 10.1016/s0140-6736(81)90853-9. PMID: 6115178.


10: Tunn UW. Cyproterone acetate in the management of prostatic cancer. Prog Clin Biol Res. 1989;303:105-10. PMID: 2528734.


11: de Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti- androgen, in the treatment of prostate cancer. Prostate Suppl. 1992;4:91-5. doi: 10.1002/pros.2990210514. PMID: 1533452.


12: Miller JA, Jacobs HS. Treatment of hirsutism and acne with cyproterone acetate. Clin Endocrinol Metab. 1986 May;15(2):373-89. doi: 10.1016/s0300-595x(86)80031-7. PMID: 2941191.


13: Greenwood R, Burke B, Brummitt L, Cunliffe WJ. Cyclic cyproterone/ethinyloestradiol for acne. Lancet. 1983 Oct 1;2(8353):796. doi: 10.1016/s0140-6736(83)92331-0. PMID: 6137631.


14: Cooper AJ, Cernovovsky Z. The effects of cyproterone acetate on sleeping and waking penile erections in pedophiles: possible implications for treatment. Can J Psychiatry. 1992 Feb;37(1):33-9. doi: 10.1177/070674379203700108. PMID: 1532338.


15: Davies TS. Cyproterone acetate for male hypersexuality. J Int Med Res. 1974;2(2):159-63. doi: 10.1177/030006057400200211. PMID: 4468912.


16: von Mühlendahl KE, Korth-Schütz S, Müller-Hess R, Helge H, Weber B. Cyproterone acetate and adrenocortical function. Lancet. 1977 May 28;1(8022):1160-1. doi: 10.1016/s0140-6736(77)92426-6. PMID: 68264.


17: Schuppler J, Günzel P. Letter: Cyproterone acetate. Lancet. 1976 Sep 25;2(7987):688. doi: 10.1016/s0140-6736(76)92498-3. PMID: 60545.


18: Byrne A, Brunet B, McGann P. Cyproterone acetate therapy and aggression. Br J Psychiatry. 1992 Feb;160:282-3. doi: 10.1192/bjp.160.2.282. PMID: 1531776.


19: Bercovici JP. Acétate de cyprotérone [Cyproterone acetate]. Ann Endocrinol (Paris). 1983;44(6):385. French. PMID: 6234848.


20: Kauli R, Pertzelan A, Prager-Lewin R, Grünebaum M, Laron Z. Cyproterone acetate in treatment of precocious puberty. Arch Dis Child. 1976 Mar;51(3):202-8. doi: 10.1136/adc.51.3.202. PMID: 952553; PMCID: PMC1545909.